154 related articles for article (PubMed ID: 18821564)
1. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder.
Mick E; Neale B; Middleton FA; McGough JJ; Faraone SV
Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1412-8. PubMed ID: 18821564
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.
Mick E; McGough JJ; Middleton FA; Neale B; Faraone SV
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):466-72. PubMed ID: 21130132
[TBL] [Abstract][Full Text] [Related]
3. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
Angyal N; Horvath EZ; Tarnok Z; Richman MJ; Bognar E; Lakatos K; Sasvari-Szekely M; Nemoda Z
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):122-128. PubMed ID: 29374517
[TBL] [Abstract][Full Text] [Related]
4. The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder.
Park S; Kim BN; Cho SC; Kim JW; Kim JI; Shin MS; Yoo HJ; Han DH; Cheong JH
J Child Adolesc Psychopharmacol; 2014 May; 24(4):223-7. PubMed ID: 24815731
[TBL] [Abstract][Full Text] [Related]
5. Regional brain perfusion before and after treatment with methylphenidate may be associated with the G1287A polymorphism of the norepinephrine transporter gene in children with attention-deficit/hyperactivity disorder.
Park MH; Kim JW; Yang YH; Hong SB; Park S; Kang H; Kim BN; Shin MS; Yoo HJ; Cho SC
Neurosci Lett; 2012 Apr; 514(2):159-63. PubMed ID: 22405810
[TBL] [Abstract][Full Text] [Related]
6. Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.
Lee SH; Kim SW; Lee MG; Yook KH; Greenhill LL; Fradin KN; Hong HJ
Psychiatry Res; 2011 Apr; 186(2-3):338-44. PubMed ID: 20863575
[TBL] [Abstract][Full Text] [Related]
7. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393
[TBL] [Abstract][Full Text] [Related]
8. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
Johnson KA; Barry E; Lambert D; Fitzgerald M; McNicholas F; Kirley A; Gill M; Bellgrove MA; Hawi Z
J Child Adolesc Psychopharmacol; 2013 Dec; 23(10):655-64. PubMed ID: 24350812
[TBL] [Abstract][Full Text] [Related]
10. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study in German patients with attention deficit/hyperactivity disorder.
Hinney A; Scherag A; Jarick I; Albayrak Ö; Pütter C; Pechlivanis S; Dauvermann MR; Beck S; Weber H; Scherag S; Nguyen TT; Volckmar AL; Knoll N; Faraone SV; Neale BM; Franke B; Cichon S; Hoffmann P; Nöthen MM; Schreiber S; Jöckel KH; Wichmann HE; Freitag C; Lempp T; Meyer J; Gilsbach S; Herpertz-Dahlmann B; Sinzig J; Lehmkuhl G; Renner TJ; Warnke A; Romanos M; Lesch KP; Reif A; Schimmelmann BG; Hebebrand J;
Am J Med Genet B Neuropsychiatr Genet; 2011 Dec; 156B(8):888-97. PubMed ID: 22012869
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD: relation to maternal smoking during pregnancy.
Thakur GA; Sengupta SM; Grizenko N; Choudhry Z; Joober R
PLoS One; 2012; 7(11):e49616. PubMed ID: 23185385
[TBL] [Abstract][Full Text] [Related]
13. Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.
Park S; Kim JW; Yang YH; Hong SB; Park MH; Kim BN; Shin MS; Yoo HJ; Cho SC
Behav Brain Funct; 2012 May; 8():22. PubMed ID: 22591463
[TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
15. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1).
Kooij JS; Boonstra AM; Vermeulen SH; Heister AG; Burger H; Buitelaar JK; Franke B
Am J Med Genet B Neuropsychiatr Genet; 2008 Mar; 147B(2):201-8. PubMed ID: 17955457
[TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.
Kereszturi E; Tarnok Z; Bognar E; Lakatos K; Farkas L; Gadoros J; Sasvari-Szekely M; Nemoda Z
Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1431-5. PubMed ID: 18214865
[TBL] [Abstract][Full Text] [Related]
17. Replication of a rare protective allele in the noradrenaline transporter gene and ADHD.
Xu X; Hawi Z; Brookes KJ; Anney R; Bellgrove M; Franke B; Barry E; Chen W; Kuntsi J; Banaschewski T; Buitelaar J; Ebstein R; Fitzgerald M; Miranda A; Oades RD; Roeyers H; Rothenberger A; Sergeant J; Sonuga-Barke E; Steinhausen HC; Faraone SV; Gill M; Asherson P
Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1564-7. PubMed ID: 18937296
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations.
Lasky-Su J; Neale BM; Franke B; Anney RJ; Zhou K; Maller JB; Vasquez AA; Chen W; Asherson P; Buitelaar J; Banaschewski T; Ebstein R; Gill M; Miranda A; Mulas F; Oades RD; Roeyers H; Rothenberger A; Sergeant J; Sonuga-Barke E; Steinhausen HC; Taylor E; Daly M; Laird N; Lange C; Faraone SV
Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1345-54. PubMed ID: 18821565
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3).
Purper-Ouakil D; Wohl M; Orejarena S; Cortese S; Boni C; Asch M; Mouren MC; Gorwood P
Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1425-30. PubMed ID: 18563707
[TBL] [Abstract][Full Text] [Related]
20. Association between the GRM7 rs3792452 polymorphism and attention deficit hyperacitiveity disorder in a Korean sample.
Park S; Jung SW; Kim BN; Cho SC; Shin MS; Kim JW; Yoo HJ; Cho DY; Chung US; Son JW; Kim HW
Behav Brain Funct; 2013 Jan; 9():1. PubMed ID: 23295062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
